OncoMatch/Clinical Trials/NCT07280832
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Is NCT07280832 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies JMT108 for unresectable locally advanced or metastatic melanoma.
Treatment: JMT108 — This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Received chemotherapy...within 4 weeks prior to the first administration of the study drug.
Cannot have received: radiotherapy
Received...radiotherapy...within 4 weeks prior to the first administration of the study drug.
Cannot have received: biotherapy
Received...biotherapy...within 4 weeks prior to the first administration of the study drug.
Cannot have received: endocrine therapy
Received...endocrine therapy...within 4 weeks prior to the first administration of the study drug.
Cannot have received: targeted therapy
Received...targeted therapy...within 4 weeks prior to the first administration of the study drug.
Cannot have received: immunotherapy
Received...immunotherapy...within 4 weeks prior to the first administration of the study drug.
Cannot have received: other unapproved clinical trial drugs or treatments
Received...other unapproved clinical trial drugs or treatments within 4 weeks prior to the first administration of the study drug.
Cannot have received: IL-2/IL-15 cytokine therapy
Prior use of IL-2/IL-15 cytokine therapy.
Lab requirements
Blood counts
Kidney function
Liver function
Participants with adequate organ functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify